Therapeutische Umschau Revue Therapeutique · Oct 2026
Symptomatic treatment of cardiac transthyretin amyloidosis
By Pfister O
The symptomatic management of transthyretin amyloid cardiomyopathy (ATTR-CM) requires continuous clinical assessment of volume status, blood pressure, heart rate and rhythm, and renal function. The cornerstone of treatment is carefully titrated decongestion with loop diuretics, often supplemented by sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs). Renin-angiotensin-aldosterone system (RAAS) inhibitors and beta blockers are not routinely recommended as standard therapy but may be used cautiously in selected patients with a clear additional indication. In patients with atrial fibrillation, avoiding excessive heart-rate reduction, considering rhythm-control strategies at an early stage, and ensuring consistent anticoagulation are particularly important. Conduction abnormalities should be actively screened for and, when pacing is indicated, treated using the most physiologic pacing strategy feasible. All symptomatic measures complement, but do not replace, disease-modifying therapy for ATTR-CM.